EMFLAZA® (deflazacort) is NOW indicated for the treatment of Duchenne muscular dystrophy
in patients 2 YEARS OF AGE AND OLDER. LEARN MORE ›
SEE HOW CORTICOSTEROIDS MAY HELP YOUR CHILD
Corticosteroids are medicines that relieve inflammation and are similar to the hormones your body naturally produces.1
The American Academy of Neurology and the U.S. Centers for Disease Control and Prevention both recommend the use of corticosteroids as a building block of Duchenne treatment.2,3
the benefits of corticosteroids
Discuss the benefits of corticosteroids with your healthcare team. Adding corticosteroids such as EMFLAZA® (deflazacort) to your treatment plan can also be effective in keeping muscle strength.4
Some helpful facts to know about corticosteroids2,5
Corticosteroids are considered a building block of DMD treatment
The American Academy of Neurology (AAN) and the U.S. Centers for Disease Control and Prevention (CDC) guidelines recommend corticosteroids as a building block of treatment for DMD.
Corticosteroids should always be taken exactly as prescribed
And make sure to schedule regular visits with healthcare providers who are skilled in managing treatment.
Other medicines may cause interactions with corticosteroids
Always tell your healthcare provider, nurses, and other specialists that you’re using corticosteroids.
Patients should never abruptly stop taking corticosteroids
Do not stop corticosteroid treatment without speaking to your healthcare provider first.
Always consult your healthcare provider
If you have missed a dose or if you are experiencing any side effects with corticosteroid treatment.
1. Corticosteroid (oral route, parenteral route). Mayo Clinic website. https://www.mayoclinic.org/drugs-supplements/corticosteroid-oral-route-parenteral-route/description/drg-20070491. Accessed April 1, 2018. 2. Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9(1):77-93. 3. Gloss D, Moxley RT, Ashwal S, et al. Practice guideline update summary: corticosteroid treatment of Duchenne muscular dystrophy: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016;86(5):465-472. 4. Merlini L, Gennari M, Malaspina E, et al. Early corticosteroid treatment in 4 Duchenne muscular dystrophy patients: 14-year follow-up. Muscle Nerve. 2012;45(6):796-802. 5. Birnkrant DJ, Bushby K, Bann CM, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17(3):251-267.